Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Ray MannehMauricio LemaLucía Carril-AjuriaLinda IbatáSusan MartínezDaniel CastellanoGuillermo de VelascoPublished in: Biomedicines (2022)
This meta-analysis shows that combinations of IO-KI as first-line treatment in favorable-IMDC-risk aRCC improve PFS, ORR, and CR, but not OS, versus sunitinib.